CYP2D6 Copy Number Determination using Digital PCR

Accurate prediction of CYP2D6 activity from genotype data is of utmost importance as CYP2D6 pharmacogenetic (PGx) testing is increasingly used to guide drug therapy. However, given the complexity of the highly polymorphic CYP2D6 gene locus, PGx testing is not trivial and presents considerable challenges especially regarding copy number testing to capture the many structural variants. In this webinar, we will introduce a streamlined digital PCR method utilizing the Applied Biosystems™ QuantStudio™ Absolute Q™ dPCR System to detect CYP2D6 structural variation. This method integrates “one-pot” enzymatic restriction digestion with a custom triplex TaqMan™ copy number variation (CNV) assay, enabling the detection of three CYP2D6 reg ons in a single dPCR reaction. We will demonstrate how this approach enables accurate, reliable CNV quantification for CYP2D6 across various sample types including blood, saliva, and liver tissue. Join us to explore how this technique can help overcome common challenges in CYP2D6 evaluation, ultimately aiding in more accurate and effective drug therapy research and potential clinical testing.

 

For Research Use Only. Not for use in diagnostic procedures.

 

^© 2024 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. TaqMan is a trademark of Roche Molecular Systems, Inc., used under permission and license.